Markel has launched Life Science Combined, a specialist insurance proposition for small and medium-sized enterprises operating in the life sciences sector.
The product is designed to address risks faced by businesses across research, development, and production stages.
The UK life sciences sector employs more than 359,600 people and generates £146.9 billion in turnover. Markel said the proposition was developed in collaboration with broker partners and end customers based on sector feedback.
Life Science Combined is aimed at organisations in the life sciences, cosmetics, and vitamins and food supplements sectors. It also covers service providers including contract research and manufacturing organisations, regulatory consultancies, laboratories, and software developers.
The product provides coverage from early-stage testing through to product launch and distribution. It addresses sector-specific risks such as medical malpractice, product efficacy, cyber, and clinical trials.
Brokers placing risks through the proposition will have access to Markel's underwriters across the UK. Clients will also have access to value-added services including a 24/7 cyber incident toolkit, in-house legal advice, tax support for funding and relief opportunities, and crisis PR support.
Lee Mooney (pictured above), UK managing director at Markel, said the proposition will enable the company to grow its presence in the sector and support its plans for 2026 and beyond.
"By delivering tailored solutions that address complex risks and provide added-value services, we are helping brokers strengthen client relationships and unlock new opportunities," Mooney said.
The launch follows a period of growth for the Markel Group, which reported an 11% increase in gross written premiums and a 6% rise in operating revenues for the quarter ended 30 September 2025.
Life Science Combined is also part of a broader expansion into specialist markets. In November 2025, Markel introduced a construction and engineering practice within its international division, appointing Anna Woolley as director to lead the new practice.
